Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension:...

Area of Science:

• Cardiology
• Nephrology
• Medical Devices

Background:

• Perirenal adipose tissue (PRAT) plays a role in hypertension via afferent nerves.
• PRAT is a potential target for managing elevated blood pressure.

Purpose of the Study:

• To assess the feasibility and safety of a novel focused power ultrasound device for perirenal adipose tissue modification (PRATM) therapy.
• To evaluate PRATM therapy in patients with essential hypertension.

Main Methods:

• A single-center, prospective pilot trial involving 20 patients with essential hypertension.
• Patients received PRATM therapy and were followed for 3 months.
• Primary endpoint: all-cause mortality or device-related adverse events (AEs).

Main Results:

• Four patients experienced transient mild lumbar pain; one had mild skin redness. No serious AEs were observed.
• Office systolic blood pressure (OSBP) decreased by 18.2 mmHg and office diastolic blood pressure (ODBP) by 2.8 mmHg at 3 months.
• Ambulatory blood pressure monitoring showed reductions in 24-hour systolic and diastolic blood pressure at 3 months, though confidence intervals included zero.

Conclusions:

• Perirenal adipose tissue modification (PRATM) demonstrates preliminary feasibility and safety for hypertension management.
• Larger, randomized trials are necessary to confirm efficacy and long-term safety of PRATM.